Detalles de la búsqueda
1.
Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
Am J Transplant
; 22(4): 1133-1144, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910841
2.
Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
Am J Transplant
; 21(12): 3907-3918, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34236770
3.
Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
Am J Transplant
; 19(2): 381-390, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29981209
4.
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Am J Transplant
; 19(11): 3035-3045, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31257724
5.
Update on the use of immunoglobulin in human disease: A review of evidence.
J Allergy Clin Immunol
; 139(3S): S1-S46, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28041678
6.
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Kidney Int
; 91(3): 729-737, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28104301
7.
Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches.
Curr Opin Organ Transplant
; 19(6): 591-7, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25304815
8.
Rituximab and intravenous immune globulin for desensitization during renal transplantation.
N Engl J Med
; 359(3): 242-51, 2008 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-18635429
9.
Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy.
Clin Exp Nephrol
; 15(1): 164-70, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21107633
10.
Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).
Transplantation
; 105(8): 1808-1817, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33093408
11.
Advances in diagnosing and managing antibody-mediated rejection.
Pediatr Nephrol
; 25(10): 2035-45; quiz 2045-8, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20077121
12.
Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts.
J Clin Apher
; 24(4): 155-60, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19658162
13.
Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Transplantation
; 103(12): 2666-2674, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30883456
14.
Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant.
Am J Kidney Dis
; 59(6): 758-60, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22464877
15.
Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection.
Transplantation
; 101(10): 2419-2428, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28557957
16.
Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Transplantation
; 101(4): 883-889, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27495773
17.
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Transplantation
; 99(2): 299-308, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25606785
18.
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Transplantation
; 99(7): 1423-30, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25606792
19.
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Transplantation
; 99(11): 2356-63, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26018350
20.
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Transplantation
; 98(3): 312-9, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24770617